1h Free Analyst Time
The stem cell umbilical cord blood (UCB) market is forecasted to grow by USD 1.68 billion during 2023-2028, accelerating at a CAGR of 18.5% during the forecast period. The report on the stem cell umbilical cord blood (UCB) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of several chronic disorders, increased federal investment in stem cell therapy, and advent of cord blood banking.
The stem cell umbilical cord blood (UCB) market is segmented as below:
By End-user
- Pharmaceutical
- Research institutes
- Hospitals
- Biobanks
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
The report on the stem cell umbilical cord blood (UCB) market covers the following areas:
- Stem Cell Umbilical Cord Blood (UCB) Market sizing
- Stem Cell Umbilical Cord Blood (UCB) Market forecast
- Stem Cell Umbilical Cord Blood (UCB) Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global stem cell umbilical cord blood (UCB) market: Americord Registry LLC, Athersys Inc., CBR Systems Inc., Cells4Life Group LLP, Celularity Inc., Cordlife Group Ltd., CRYO-CELL International Inc, Cryo Stemcell, Cryoviva Biotech Pvt. Ltd., FamiCord Group, FUTURE CELL JAPAN, Global Cord Blood Corp., LifeCell International Pvt. Ltd., MEDIPOST Co. Ltd., Next Biosciences Pty Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Smith and Nephew plc, ViaCord LLC, and Vita 34 AG.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing investments in field of regenerative medicines."
According to the report, one of the major drivers for this market is the rising prevalence of several chronic disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Americord Registry LLC
- Athersys Inc.
- CBR Systems Inc.
- Cells4Life Group LLP
- Celularity Inc.
- Cordlife Group Ltd.
- CRYO-CELL International Inc
- Cryo Stemcell
- Cryoviva Biotech Pvt. Ltd.
- FamiCord Group
- FUTURE CELL JAPAN
- Global Cord Blood Corp.
- LifeCell International Pvt. Ltd.
- MEDIPOST Co. Ltd.
- Next Biosciences Pty Ltd.
- Regrow Biosciences Pvt Ltd.
- Smart Cells International Ltd.
- Smith and Nephew plc
- ViaCord LLC
- Vita 34 AG